#### PLEXION- sulfacetamide sodium, sulfur cloth Brava Pharmaceuticals, LLC

Disclaimer: This drug has not been found by FDA to be safe and effective, and this labeling has not been approved by FDA. For further information about unapproved drugs, click here.

-----

## PLEXION (sodium sulfacetamide 9.8%, sulfur 4.8%) Cleansing Cloths


#### **Rx Only**

FOR EXTERNAL USE ONLY. NOT FOR OPHTHALMIC USE.

## **DESCRIPTION:**

Each cloth is coated with a cleanser-based formulation. Each gram of solution contains 98 mg of sodium sulfacetamide and 48 mg of colloidal sulfur in a vehicle consisting of: benzyl alcohol, cetyl alcohol, fragrance, glyceryl stearate (and) PEG-100 stearate, magnesium aluminum silicate, phenoxyethanol, propylene glycol, purified water, sodium lauryl sulfate, sodium magnesium silicate, sodium thiosulfate, stearyl alcohol and xanthan gum.

Sodium sulfacetamide is a sulfonamide with antibacterial activity while sulfur acts as a keratolytic agent. Sodium sulfacetamide is C  $_8H_9N_2NaO_3SH_2O$  with molecular weight of 254.24. Chemically, sodium sulfacetamide is N-[(4-aminophenyl) sulfonyl]-acetamide, monosodium salt, monohydrate. The structural formula is:



Sodium sulfacetamide is an odorless, white, crystalline powder with a bitter taste. It is freely soluble in water, sparingly soluble in alcohol, while practically insoluble in benzene, in chloroform and in ether.

# **CLINICAL PHARMACOLOGY:**

Sodium sulfacetamide exerts a bacteriostatic effect against sulfonamide sensitive Gram-positive and Gram-negative microorganisms commonly isolated from secondary cutaneous pyogenic infections. It acts by restricting the synthesis of folic acid required by bacteria for growth, by its competition with para-aminobenzoic acid. There is no clinical data available on the degree and rate of systemic absorption of this product when applied to the skin or scalp. However, significant absorption of sodium sulfacetamide through the skin has been reported.

The following in vitro data is available but the clinical significance is unknown. Organisms that show susceptibility to sodium sulfacetamide are: Streptococci, Staphylococci, E. coli, Klebsiella pneumoniae, Pseudomonas pyocyanea, Salmonella species, Proteus vulgaris, Nocardia and Actinomyces.

The exact mode of action of sulfur in the treatment of acne is unknown, but it has been reported that it inhibits the growth of *Propionibacterium acnes* and the formation of free fatty acids.

## **INDICATIONS AND USAGE:**

This product is indicated for use in the topical control of acne vulgaris, acne rosacea and seborrheic dermatitis.

## **CONTRAINDICATIONS:**

This product is contraindicated in persons with known or suspected hypersensitivity to any of the ingredients of the product. This product is not to be used by patients with kidney disease.

## WARNINGS:

Sulfonamides are known to cause Stevens-Johnson syndrome in hypersensitive individuals. Stevens-Johnson syndrome also has been reported following the use of sodium sulfacetamide topically. Cases of drug-induced systemic lupus erythematosus from topical sulfacetamide also have been reported. In one of these cases, there was a fatal outcome. **KEEP OUT OF THE REACH OF CHILDREN.** 

## **PRECAUTIONS:**

## FOR EXTERNAL USE ONLY. NOT FOR OPHTHALMIC USE.

**General:** Nonsusceptible organisms, including fungi, may proliferate with the use of this preparation.

Although rare, sensitivity to sodium sulfacetamide may occur. Therefore, caution and careful supervision should be observed when prescribing this drug for patients who may be prone to hypersensitivity to topical sulfonamides. If the use of this product produces signs of hypersensitivity or other untoward reactions, discontinue use of the preparation. Patients should be carefully observed for possible local irritation or sensitization during long-term therapy. Systemic toxic reactions such as agranulocytosis, acute hemolytic anemia, purpura hemorrhagica, drug fever, jaundice and contact dermatitis indicate hypersensitivity to sulfonamides. Particular caution should be employed if areas of denuded or abraded skin are involved. Systemic absorption of topical sulfonamides is greater following application to large, infected, abraded, denuded or severely burned areas. Under these circumstances, any of the adverse effects produced by the systemic administration of these agents could potentially occur, and appropriate observations and laboratory determinations should be performed.

The object of this therapy is to achieve desquamation without irritation, but sodium sulfacetamide and sulfur can cause reddening and scaling of the epidermis. These side effects are not unusual in the treatment of acne vulgaris, but patients should be cautioned about the possibility.

**Information for Patients :** Patients should discontinue the use of this product if the condition becomes worse or if a rash develops in the area being treated or elsewhere. The use of this product also should be discontinued promptly and the physician notified if any arthritis, fever or sores in the mouth develop. Avoid contact with eyes, lips and mucous membranes.

**Drug Interactions:** This product is incompatible with silver preparations.

**Carcinogenesis, Mutagenesis and Impairment of Fertility:** Long-term animal studies for carcinogenic potential have not been performed on this product to date. Studies on reproduction and fertility also have not been performed. Chromosomal nondisjunction has been reported in the yeast, Saccharomyces cerevisiae, following application of sodium sulfacetamide. The significance of this finding to the topical use of sodium sulfacetamide in the human is unknown.

**Pregnancy:***Category C.* Animal reproduction studies have not been conducted with this product. It is also not known whether this product can affect reproduction capacity or cause fetal harm when administered to a pregnant woman. This product should be used by a pregnant woman only if clearly needed or when potential benefits outweigh potential hazards to the fetus.

**Nursing Mothers:** It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when this product is administered to a nursing woman.

**Pediatric Use:** Safety and effectiveness in children under the age of 12 years have not been established.

#### **ADVERSE REACTIONS:**

Reports of irritation and hypersensitivity to sodium sulfacetamide are uncommon. The following adverse reactions, reported after administration of sterile ophthalmic sodium sulfacetamide, are noteworthy: instances of Stevens-Johnson syndrome and instances of local hypersensitivity which progressed to a syndrome resembling systemic lupus erythematosus; in one case a fatal outcome was reported (see WARNINGS).

## **OVERDOSAGE:**

The oral LD  $_{50}$  of sulfacetamide in mice is 16.5 g/kg. In the event of overdosage, emergency treatment should be started immediately.

**Manifestations:** Overdosage may cause nausea and vomiting. Large oral overdosage may cause hematuria, crystalluria and renal shutdown due to the precipitation of sulfa crystals in the renal tubules and the urinary tract. For treatment, contact your local Poison Control Center or your doctor.

## DOSAGE AND ADMINISTRATION:

Wash affected areas with this product once or twice daily or as directed by a physician. Moisten skin and cleansing cloth with water. Work cloth into full lather and massage gently into skin for 10 to 20 seconds, rinse thoroughly and pat dry. Discard cloth in refuse container. If drying occurs, it may be controlled by rinsing affected area sooner or using product less frequently.

## **STORAGE:**

Store at 20°C to 25°C (68°F to 77°F), excursions permitted between 15°C and 30°C (between 59°F and 86°F). Brief exposure to temperatures up to 40°C (104°F) may be tolerated provided the mean kinetic temperature does not exceed 25°C (77°F); however, such exposure should be minimized.

**NOTICE:** Protect from freezing and excessive heat. The product may tend to darken slightly on storage. Slight discoloration does not impair the efficacy or safety of the product.

Occasionally, a slight discoloration of fabric may occur when an excessive amount of the product is used and comes in contact with white fabrics. This discoloration, however, presents no problem, as it is readily removed by ordinary laundering without bleaches.

## **HOW SUPPLIED:**

60 count carton, **NDC** 57883-404-60

**To report** a serious adverse event or obtain product information, call 1-855-899-4237.

Manufactured for:

Artesa Labs, LLC

13785 Research Blvd, Suite 125

Austin, TX 78750

1800037 v1 Rev. 07/2018

#### (continued from side panel)

WARNINGS: Sufficient and the active stream is cause Stevens-Johnson syndrome in hypersensitive individuals, Stevens-Johnson syndrome also has been reported figaving the use of addim united active to the state of the state of the stream of the lapue orthomatorus from foecial outcatantide date have been reported, in ore of these cause, there was a faired active. KEEP OUT OF REACH OF CHILDREN.

\_..\_..

PRECAUTIONS: FOR EXTERNAL USE ONLY, NOT FOR OPHTHALMIC USE. Do not use If packet is term or punctured.

General: Nonsusceptible organisms, including fungi, may proliferate with the use of this proparation,

Although net, persitivity to adjust adjusted and execut. Therefore, curies and exercise approximation should be observed when presonating this drug to probates when may be prove to hypereventitivity or after universities. If the use of this product produces sign of hypereventitivity or after universities. If the use of this product produces product a should be carefully discrete for passible local inflation or avanitations during any any structure to the product and the product and the product anothing support to the product and the product and the product anothing support to the product and the product and the product anothing support to the product and the product and the product anothing support to the product and the product and the product anothing application to large, indicate and any advanced be employed in allowing and applications to large, indicate and any advanced be and product anothing application to large, indicate and any advanced be and product and anothing the product and the product absorption of topical automoves in any advanced by these appends could application to large denoted by any advanced by a product to large application to

The object of this therapy is to achieve desguarration without initiation, but sotium suffocetamise and suffur can cause reddening and scafing of the epidemis, These side effects are not unusual in the treatment of some vulgaris, but patients should be cautioned about the possibility.


Information for Patients: Patients should discontinue the use of this product if the condition becomes worse or if a rank develops in the area being treated or ejsewhere the use of this product doe should be discontinue dramply and the physician natified if any arthritis, there or series in the msuft develop. Avoid centiact with eyes, lips and mucaus membranes.

Drug Interactions: This product is incompatible with silver preparations.

Carcinogenesis, Mutagenesis and Impairment of Fertility: Long-term animal studies for carcinogenic potential have not been performed on this product to data. Studies on representation and startilly also have not been performed. Chromecennal modisjunction has been reported in the yeast, Succharamyces corrections, following application of calcium sufficient mice. The significance of this finding to the topical use of socium sufficient in the human is unknown.

Pergnaney: Category C. Anim I reproduction studies have not been conducted with this poduct. It is also not harow whether this product can affect reproduction capacity or cause fold harm when adminishered to a program townars. This product shuld be used by a pregnant warran only if dourly needed or when potential barrefits outweigh potential hazarist to be focus.

Nursing Mothers: It is not known whether this drug is exceted in human milk. Because many drugs are excerned in human milk, caution should be exercised when this product is administered to a nursing woman.



(continued from back penel)

Pediatric Use: Safety and effectiveness in children under the age of 12 years have not been established. ADVERSE REACTIONS: Reports of imitation and hypersensitivity to

sedium sufficeriamide are uncommon. The following adverse reactions, reported after administration of starile sphthelimic sedium suffacetamide, are noteworthy: instances of Stavens-Johnson availome and instances of local tweensensity/by

which progressed to a syndrome resembling systemic jupus erythematosus; in one case a fatal outcome was reported (see WARNINGS).

OVERDOSAGE: The end  $LD_{10}$  of subscetamide in mice is 16.5 g/kg. In the event of overdesage, emergency treatment should be started immediately.

Manifestations: Overdosage may cause nausea and vomiting, Large oral eventosage may cause hematuria, crystaljuria and renal shutdown due to the procletation of sudia crystals in the renal tubules and the uninary truct. For treatment, contact your local Poison Control Conter or your doctor.

DOSAGE AND ADMONSTRATION: Wash affected areas with this product once or Wate and/or as a directed by a physician. Mathem she and devening down with water Wate Atabi Into Alastina and massage genity may she for 10 a 20 accords, many hereating and paid of, Diozan down in matus cardinates. If drying accurs, it may be controlled by riseting affected area somer or using productions they emity.

STORAGE: Store at 20°C to 25°C (85°F to 77°F), accursions permitted between 15°C and 30°C (between 59°F and 86°F). Belf exposure to temperatures up to 40°C (164°F) may be talerated provided the mean kinetic temperature does not acceed 25°C (27°F): however, such exposure should be temimized.

NOTICE: Protect from freezing and excessive heat. The product may tend to dorken slightly on storage. Slight discoloration does not impair the efficacy or safety of the product.

Occasionally, a slight discoloration of fabric may occur when an excessive amount of the product is used and corres in contact with while fabrics. This discolaration, however, presents no problem it is readily removed by antinary laundering without bleaches.

HOW SUPPLIED: 60 count carton, NDC 57883-404-60


To report a serious adverse event or obtain product information, call 1-355-899-4237,

Distributed by: Artera Labs, LLC 13748 Research Bjed, Suite 125 Austin, 17.78750 1400037 v1 Rev. 07/2018



NDC 57883-404-60

Artesa Labs



#### PLEXION® Cleansing Cloths Rx Only (sodium suffacetamide 9,8%, suffur 4,8%)

FOR EXTERNAL USE ONLY, NOT FOR OPHTHALMIC USE.

DESCEPTIONE Each dorh is context with a demonst-based formalistion. Each grain of solution contains 96 mg of social adjusted miles and 46 mg of collocid adult in a vehicle contaiting of bency lacebit conditioned in a vehicle contained (PEG-100 stereture, magnetism adjuster) manufer, bency thank progene gived, purtile winks, sodium band sufficient, sodium magnetium siteste, sodium throughte, steret data and xanthan gum.

Sodium suffacetamide is a sufferiamide with antibacterial activity while suffur acts as a keratelytic agent, Sodium suffacetamide is Catify(kat)pSH<sub>2</sub>O with molecular weight at 254,24, Chemically, sodium suffacetamide is N-(kaminghensy) suffacy[-acetamide menesodium sab, menetydrate. The structural termula is:

Sodium subacetamide is an odorless, white, crystalline powder with a bitter taste, it is freely solutile in water, sparingly solutile in alcohol, while practically insolutie in banzene, in chiereform and in other.

CLINEAL PHARMACOLOGY. Sodium advactantice centra a backnistatice effect against auforantide samples compand Gram-against encorganismic commently leaded from secondary cutaneous pogenic infections. It acts by restricting the synthesis of face, acid required by bacteria for growth, by its competition with para-antiobercoic cod. There is no diricial data available on the degree and rate o synthemic absorption of this product when applied to be skin or sodia. Newseer, significant absorption of sodium subsociamide through the skin has been reported.


The following in vitro data is evaluated but the dirical significance is unknown. Organisms that show susceptibility to sodium subactamide are: Svephococi, Staphylococci, E. celi, Klassiel a presumarice, Peudomena pycysmea, Salmonella species, Proteau subgaris, Nacardia and Actinemyces.

The exact mode of action of subur in the treatment of acne is unknown, but it has been reported that it inhibits the growth of Provioubacterium acnes and the formation of free fatty acids.

NOICATIONS: This product is indicated for use in the topical control of acre vulgaris, acre resaces and selectrheic dermatitis,

CONTRADIDICATIONS: This product is contraindicated in persons with known or suspected hypersensitivity to any of the legendients of the product. This product is not to be used by patients with kidney disease.

(continued on back panel)



# PLEXION

sulfacetamide sodium, sulfur cloth

Product Information					
Product Type	HUMAN PRESCRIPTION DRUG	Item Code (Source)	NDC:57883-404		
Route of Administration	TOPICAL				

#### **Active Ingredient/Active Moiety**

Ingredient Name	Basis of Strength	Strength
SULFACETAMIDE SODIUM (UNII: 4NRT660KJQ) (SULFACETAMIDE - UNII:4965G3J0F5)	SULFACETAMIDE SODIUM	98 mg in 1 g
SULFUR (UNII: 70FD1KFU70) (SULFUR - UNII:70FD1KFU70)	SULFUR	48 mg in 1 g

Ingredient Name					Strength
BENZYL ALCOHOL (					
CETYL ALCOHOL (U					
GLYCERYL MONOST					
PEG-100 STEARATE (					
MAGNESIUM ALUMIN					
PHENOXYETHANOL (					
PROPYLENE GLYCOL (UNII: 6DC9Q167V3)					
WATER (UNII: 059QF0	KO0R)				
SODIUM LAURYL SU	LFATE (UNII: 3	368GB5141J)			
LAPONITE (UNII: D703	3131383)				
SODIUM THIOSULFA	TE (UNII: HX10	32V43M)			
STEARYL ALCOHOL (UNII: 2KR89I4H1Y)					
XANTHAN GUM (UNII:	TTV12P4NEE)				
Product Characte	yellow Score				
		yellow	Score		
Color		yello w	Score Size		
Color Shape		yello w		ie	
Color Shape Flavor Contains		yellow	Size	le	
Color Shape Flavor		yellow	Size	le	
Color Shape Flavor		yellow	Size	ie	
Color Shape Flavor		yellow	Size	le	
Color Shape Flavor Contains Packaging		yellow Package Descriptio	Size Imprint Coc	de Marketing Start Date	Marketing End Dat
Color Shape Flavor Contains Packaging # Item Code		Package Descriptio	Size Imprint Coc		Marketing End Dat
Color Shape Flavor Contains Packaging Item Code	60 in 1 CART	Package Descriptio	n Size	Marketing Start Date	Marketing End Dat
Color  Shape  Flavor  Contains  Cont	60 in 1 CART 4 g in 1 PACK	<b>Package Descriptio</b> ON ET; Type 0: Not a Combin	n Size	Marketing Start Date	Marketing End Dat
Color  Shape  Shape  Flate  Contains  Contains	60 in 1 CART 4 g in 1 PACK 10 in 1 CART	<b>Package Descriptio</b> ON ET; Type 0: Not a Combin	nation Product	Marketing Start Date	Marketing End Dat
Color  Shape  Shape  Item Code  Item Code  NDC:57883-404-01  NDC:57883-404-10	60 in 1 CART 4 g in 1 PACK 10 in 1 CART	Package Descriptio ON ET; Type 0: Not a Combin DN	nation Product	Marketing Start Date	Marketing End Dat

Marketing Category	Application Number or Monograph Citation	Marketing Start Date	Marketing End Date
unapproved drug other		09/01/2005	

Labeler - Brava Pharmaceuticals, LLC (078786338)

Revised: 12/2019

Brava Pharmaceuticals, LLC